Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence by Hancock, D B et al.
Genome-wide meta-analysis
reveals common splice site
acceptor variant in CHRNA4
associated with nicotine dependence
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Hancock, D. B., G. W. Reginsson, N. C. Gaddis, X. Chen, N. L.
Saccone, S. M. Lutz, B. Qaiser, et al. 2015. “Genome-wide meta-
analysis reveals common splice site acceptor variant in CHRNA4
associated with nicotine dependence.” Translational Psychiatry
5 (10): e651. doi:10.1038/tp.2015.149. http://dx.doi.org/10.1038/
tp.2015.149.
Published Version doi:10.1038/tp.2015.149
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822338
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
OPEN
ORIGINAL ARTICLE
Genome-wide meta-analysis reveals common splice site
acceptor variant in CHRNA4 associated with nicotine
dependence
DB Hancock1, GW Reginsson2, NC Gaddis3, X Chen4,5, NL Saccone6, SM Lutz7, B Qaiser8, R Sherva9, S Steinberg2, F Zink2, SN Stacey2,
C Glasheen1, J Chen4, F Gu10, BN Frederiksen11, A Loukola8, DF Gudbjartsson2, I Brüske12, MT Landi10, H Bickeböller13, P Madden14,
L Farrer9,15,16,17,18,19, J Kaprio8,20,21, HR Kranzler22,23, J Gelernter24,25,26,27, TB Baker28, P Kraft29,30, CI Amos31,32,33, NE Caporaso10,
JE Hokanson34, LJ Bierut14, TE Thorgeirsson2, EO Johnson35 and K Stefansson2,36
We conducted a 1000 Genomes–imputed genome-wide association study (GWAS) meta-analysis for nicotine dependence, deﬁned
by the Fagerström Test for Nicotine Dependence in 17 074 ever smokers from ﬁve European-ancestry samples. We followed up
novel variants in 7469 ever smokers from ﬁve independent European-ancestry samples. We identiﬁed genome-wide signiﬁcant
association in the alpha-4 nicotinic receptor subunit (CHRNA4) gene on chromosome 20q13: lowest P= 8.0 × 10− 9 across all the
samples for rs2273500-C (frequency = 0.15; odds ratio = 1.12 and 95% conﬁdence interval = 1.08–1.17 for severe vs mild
dependence). rs2273500-C, a splice site acceptor variant resulting in an alternate CHRNA4 transcript predicted to be targeted for
nonsense-mediated decay, was associated with decreased CHRNA4 expression in physiologically normal human brains (lowest
P= 7.3 × 10− 4). Importantly, rs2273500-C was associated with increased lung cancer risk (N= 28 998, odds ratio = 1.06 and 95%
conﬁdence interval = 1.00–1.12), likely through its effect on smoking, as rs2273500-C was no longer associated with lung cancer
after adjustment for smoking. Using criteria for smoking behavior that encompass more than the single ‘cigarettes per day’ item,
we identiﬁed a common CHRNA4 variant with important regulatory properties that contributes to nicotine dependence and
smoking-related consequences.
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INTRODUCTION
Cigarette smoking is a major contributor to cancer, vascular
disease and lung disease, and the leading cause of preventable
mortality worldwide.1 Nicotine dependence is heritable,2 and
genome-wide association study (GWAS) analyses of smoking
behaviors and nicotine dependence have unequivocally
identiﬁed single nucleotide polymorphism (SNP) associations
within nicotinic acetylcholine receptor gene clusters on chromo-
somes 15q25 (CHRNA5-CHRNA3-CHRNB4) and 8p11 (CHRNB3-
CHRNA6).3–9 The largest prior GWAS of smoking behavior was
conducted using very large sample sizes (N up to 74 053) and
phenotypes such as smoking history (ever vs never), age of
onset, smoking cessation (former vs current) and cigarettes
per day (CPD).5–7
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To identify additional genetic loci, we conducted the largest
GWAS meta-analysis for nicotine dependence to date. We used
the Fagerström Test for Nicotine Dependence (FTND), a six-item
questionnaire with scores that range from 0 to 10 and indicate the
level of physiological dependence on nicotine.10,11 The FTND
focuses on the core criteria for dependence, including heavy use/
tolerance (for example, CPD) and withdrawal (for example, time to
ﬁrst cigarette in the morning), and although it does not capture
some factors such as craving, the FTND remains the strongest
predictor of smoking cessation among the primary measures of
nicotine dependence.12 It has also been shown to provide a robust
measure of nicotine dependence across different settings and
populations.13
In our study, we categorized nicotine dependence as mild
(FTND score 0–3 or low-level smoking), moderate (FTND score
4–6) or severe (FTND score 7–10) among study participants, all of
European-ancestry, who reported smoking more than 100
cigarettes in their lifetime. We conducted a 1000 Genomes–
imputed GWAS meta-analysis of nicotine dependence across ﬁve
study samples (total N= 17 074), identiﬁed the alpha-4 nicotinic
receptor subunit (CHRNA4) gene as a novel genome-wide
signiﬁcant locus, tested top CHRNA4 variants for replication in
ﬁve independent study samples (total N= 7469) and conducted
follow-up association testing with lung cancer using six study
samples (total N= 12 160 cases and 16 838 controls). Our results
revealed that rs2273500, a splice site acceptor SNP with important
regulatory effects for CHRNA4, was associated with risk of
developing both nicotine dependence and lung cancer.
MATERIALS AND METHODS
All protocols used in this study received institutional review board
approval at their respective sites, and all the study participants or their
legal representatives provided informed consent.
Discovery study samples, the FTND and quality control
Five samples were used to conduct our GWAS meta-analysis of nicotine
dependence: deCODE Genetics,4 Environment and Genetics in Lung
Cancer Etiology Study (EAGLE),14,15 Chronic Obstructive Pulmonary Disease
Gene (COPDGene) Study,16 Collaborative Genetic Study of Nicotine
Dependence (COGEND)3 and Study of Addiction: Genetics and Environ-
ment (SAGE*).9 These study participants, all of European-ancestry, had
genome-wide SNP genotypes and FTND10,11 scores to deﬁne nicotine
dependence among participants who reported smoking more than 100
cigarettes in their lifetime. Quality control (QC) was conducted on
genotyped participants and SNPs in each sample using PLINK17 unless
otherwise stated.
We used the FTND range of scores to categorize participants’ nicotine
dependence as mild (FTND score 0–3), moderate (FTND score 4–6) or
severe (FTND score 7–10). In the deCODE Genetics sample only, 4313 low-
intensity smokers (10 or fewer CPD) with no FTND data available were
added into the mild category. Among participants with both CPD and
FTND data available in two samples (deCODE and COGEND), we found
high concordance rates (~90%) between a report of 10 or fewer CPD and
FTND scores of 3 or less, meaning that the inclusion of low-intensity
smokers would enable us to increase sample size with little phenotype
misclassiﬁcation. As presented in Table 1, our ﬁnal analysis data sets
totaled 17 074 participants of European-ancestry: 9137 with mild, 4881
with moderate and 3056 with severe nicotine dependence.
deCODE Genetics represents a large population-based Icelandic sample.
The Icelandic cigarette smoking data have been described elsewhere.4 All
Icelandic subjects in the study of smoking-related phenotypes, including
Icelandic population controls, were originally recruited for different genetic
studies, conducted over 18 years (1996–2014) at deCODE Genetics.
Questionnaire data were used to gather information on CPD and the
FTND score. The deCODE Genetics studies were approved by the Data
Protection Commission of Iceland and the National Bioethics Committee of
Iceland. Personal identiﬁers associated with phenotypic information and
blood samples were encrypted using a third-party encryption system.18
Altogether, we included data for 9090 smokers who were genotyped using
SNP arrays in one of several GWAS conducted by deCODE Genetics.
Genotyping was carried out using Illumina (San Diego, CA, USA) chips. QC
was carried out as previously described.19
EAGLE is a population-based study of newly diagnosed lung cancer
cases and matched controls from the Italian region of Lombardy, as
described elsewhere.15 EAGLE participants, aged 35 to 79 years old, were
genotyped on the Illumina HumanHap550v3 BeadChip array, as part of the
GENEVA (Gene Environment Association Studies Initiative).20 We obtained
their genome-wide SNP genotypes, overall FTND score and other
phenotype data via the database of Genotypes and Phenotypes (dbGaP;
Table 1. Participant characteristics from 10 study samples used for the genome-wide association study (GWAS) meta-analysis or independent
replication of follow-up GWAS variants
Study sample Total N No. (%)a No. (%), male Mean age (s.d.)
Mild nicotine dependence Moderate nicotine dependence Severe nicotine dependence
GWAS meta-analysis samples
deCODE 9090 5871 (64.6) 2074 (22.8) 1145 (12.6) 4253 (46.8) 54.2 (16.7)
EAGLE 3006 1416 (47.1) 1027 (34.2) 563 (18.7) 2528 (84.1) Not availableb
COPDGene 2211 666 (30.1) 964 (43.6) 581 (26.3) 1214 (54.9) 57.7 (7.9)
COGEND 1935 941 (48.6) 521 (26.9) 473 (24.4) 750 (38.8) 36.5 (5.5)
SAGE* 832 243 (29.2) 295 (35.5) 294 (35.3) 465 (55.9) 39.4 (11.3)
Independent replication samples
FTC 2374 1345 (56.7) 793 (33.4) 236 (9.9) 1314 (55.3) 45.9 (15.6)
Yale-Penn 2116 381 (18.0) 1014 (47.9) 721 (34.1) 1247 (58.9) 37.7 (10.3)
UW-TTURC 1534 311 (20.2) 723 (47.1) 500 (32.6) 658 (42.9) 43.1 (11.5)
GAIN 774 327 (42.3) 280 (36.2) 167 (21.6) 389 (50.3) 53.8 (16.4)
nonGAIN 671 298 (44.4) 234 (34.9) 139 (20.7) 349 (52.0) 52.9 (15.5)
Abbreviations: COGEND, Collaborative Genetic Study of Nicotine Dependence; COPDGene, Chronic Obstructive Pulmonary Disease Gene Study; EAGLE,
Environment and Genetics in Lung Cancer Etiology Study; FTC, Finnish Twin Cohort Study; GAIN, Genetic Association Information Network GWAS of
schizophrenia; nonGAIN, Molecular Genetics of Schizophrenia—nonGAIN sample; SAGE*, Study of Addiction: Genetics and Environment (* indicates that
overlapping COGEND participants were excluded); UW-TTURC, University of Wisconsin-Transdisciplinary Tobacco Use Research Center. aScores on the
Fagerström Test for Nicotine Dependence (FTND) were used to categorize nicotine dependence as mild (FTND score 0–3), moderate (FTND score 4–6) or severe
(FTND score 7–10). For deCODE only, the mild category included 1558 participants with FTND score 0–3 and an additional set of 4313 low-intensity smokers
with no FTND data available but with less than 10 cigarettes per day reported. bFor EAGLE, age was only available as a categorical variable, so average age
could not be calculated. The categorical age distributions were as follows: 23.2% aged 59 or less, 18.2% aged 60–64, 22.4% aged 65–69, 21.4% aged 70–74 and
14.8% aged 75–79.
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accession number phs000093.v2.p2). Additional analyses were conducted
using the speciﬁc FTND item scores by the original study investigators. We
began by applying all participant-level and SNP-level QC procedures that
were recommended as part of the dbGaP release and then applied our
own standard set of QC procedures (Supplementary Information). There
were 3006 EAGLE participants included in our study.
COPDGene is a multicenter observational sample primarily focused on
identifying genetic risk factors for COPD, as previously described.16
Recruited participants were non-Hispanic white or African American and
aged 45 to 80 years old, who reported a history of smoking (currently or
past) and 10 or more cigarette pack-years. FTND was assessed in current
smokers only. We used the non-Hispanic white current smoking
participants for this study. Among the COPD cases, disease severity was
staged according to the Global Initiative for Chronic Obstructive Lung
Disease criteria, which are based on post-bronchodilator pulmonary
function measures. COPD controls had pulmonary function measures in
the normal range for their age and height, separately by sex. Exclusion
criteria for acute and chronic respiratory disease, cancer and other
conditions were used. COPDGene participants were genotyped on the
Illumina HumanOmni1-Quad BeadChip array. After applying our standard
QC procedures (Supplementary Information), there were 2211 COPDGene
participants for analysis.
COGEND, a community-based case–control study of nicotine-dependent
smokers vs smokers who never developed nicotine-dependence symp-
toms, began recruiting participants in 2001 from St. Louis and Detroit
through telephone screening to identify current smokers aged 25 to 44
years old.3 The FTND was administered to determine study eligibility.
Current smokers with an FTND score of ⩾ 4 were recruited as nicotine-
dependent cases, and smokers who reported4100 cigarettes during their
lifetime but an FTND score of 0 or 1 were recruited as controls. COGEND
participants were genotyped on either the Illumina Human1M-Duo
BeadChip array, as part of SAGE,9 or the Illumina HumanOmni2.5 BeadChip
array as part of GENEVA.20 In each subset, genotyped SNPs with a call rate
498% and HWE P⩾ 1× 10− 4 were retained. We combined the subsets and
removed duplicated participants and ﬁrst-degree relatives. To circumvent
bias that may arise from conducting imputation on subjects genotyped on
different arrays, we carried forward only the SNPs genotyped at the
intersection of the different arrays.21 After applying our standard QC
procedures (Supplementary Information) on the combined COGEND
sample, there remained 1935 participants for our study.
The ﬁnal GWAS sample consisted of the remaining SAGE study
participants. The full SAGE sample included participants from COGEND,
the Collaborative Study on the Genetics of Alcoholism22 and the Family
Study of Cocaine Dependence.23 For our study, we excluded the COGEND
participants to avoid redundancy. Because the remaining Collaborative
Study on the Genetics of Alcoholism and Family Study of Cocaine
Dependence participants were ascertained as part of case–control studies
of addictive disorders and all were ascertained from sites in the United
States, we analyzed them together as done in previous GWAS analyses.9
We henceforth refer to this sample as SAGE*. We obtained their Illumina
Human1M-Duo BeadChip genotypes and phenotype data via dbGaP
accession number phs000092.v1.p1. After applying our standard QC
procedures (Supplementary Information), there remained 832 participants
for analysis.
For the four samples of non-isolated populations (EAGLE, COPDGene,
COGEND and SAGE*), we used the STRUCTURE program24 to compute the
ancestral proportions of all study participants using, based on comparison
to the HapMap reference populations of Chinese (denoted CHB), European
Americans (denoted CEU) and African Americans (denoted ASW) using 10 000
SNPs randomly distributed across the genome. We excluded outlying
participants with ⩾25% Asian and/or African American proportions.
1000 Genomes imputation
Genotype imputation was conducted in each non-isolated sample using
IMPUTE2 (ref. 25) with reference to the 1000 Genomes ALL phase I
integrated variant set.25,26 Additional details are provided in the Supplementary
Information. Following imputation and removal of SNPs and insertions/
deletions (indels) with minor allele frequency o0.01 in the 1000 Genomes
EUR panel (collection of ﬁve European-ancestry populations), we tested
8 548 225 SNPs and 1 395 199 indels for association with nicotine
dependence across the samples. We used the info metric to evaluate
the SNP/indel imputation quality rather than imposing an imputation
quality ﬁlter and possibly missing truly associated SNPs/indels.27 The SNP
and indel genotype probabilities were converted to dosages and used in
the regression model for association testing with nicotine dependence to
account for any imputation uncertainty.28
For deCODE, genotype imputation was conducted by long-range
phasing of all chip-genotyped individuals with methods described
previously.29 Sequence variants were imputed from the deCODE whole-
genome sequencing effort into 104 220 chip-genotyped Icelanders, who
had been phased with long-range phasing, using the same model as used
by IMPUTE.28
Statistical analyses: testing genome-wide SNP and indel
associations with nicotine dependence
The genotyped and 1000 Genomes–imputed SNPs and indels were tested
for association with categorical nicotine dependence (mild, moderate and
severe) using ProbAbel software30 in each sample with linear regression
models that included age, sex and sample-speciﬁc covariates (if applicable,
see Supplementary Information). The four European American and Italian
samples also included principal component eigenvectors to minimize bias
owing to population stratiﬁcation; for each sample, we selected the
number of eigenvectors needed to account for 475% of the variability in
nicotine dependence.
The sample-speciﬁc GWAS results were combined in METAL31 using
inverse variance-weighted meta-analysis. The standard GWAS threshold
(Po5× 10− 8) was used to declare statistically signiﬁcant results. The I2
index was used to assess heterogeneity across samples.32
Follow-up SNP/indel association testing with nicotine dependence
in independent samples
For any novel region having genome-wide signiﬁcant association with
nicotine dependence, we selected SNPs and indels associated at meta-
analysis Po5× 10− 5 for follow-up testing across ﬁve independent
European-ancestry samples: Yale-Penn study,33–35 Finnish Twin Cohort
Study (FTC),36,37 University of Wisconsin-Transdisciplinary Tobacco Use
Research Center (UW-TTURC),12 Genetic Association Information Network
(GAIN) GWAS of Schizophrenia and Molecular Genetics of Schizophrenia—
nonGAIN Sample.
Participants in the Yale-Penn study were from small nuclear families and
unrelated individuals recruited in the eastern United States in the course of
studies of the genetics of alcohol, cocaine or opioid dependence. Nicotine
dependence had no role in subject selection. Yale-Penn participants were
administered the Semi-Structured Assessment for Drug Dependence and
Alcoholism and were genotyped on the Illumina HumanOmni1-Quad v1.0
microarray. Participants with missing rate 42% were excluded. SNPs with
missing rate42%, HWE Po1× 10− 4 and with signiﬁcantly different minor
allele frequency across genotyping labs (Yale or CIDR) were set to missing
before imputation. SNP genotype imputation was performed with
IMPUTE2 (ref. 25) using genotyped SNPs and the March 2012 1000
Genomes ALL reference panel. Genetic relationships were examined by
calculating pairwise identity-by-state estimates using PLINK.17 Sample
duplicates (identity-by-state 490%) were removed, pairs of individuals
whose identity-by-state proportions did not match their reported genetic
relationship were assigned to two different families and pairs of individuals
who shared 425% of their alleles identity-by-state were assigned to the
same family. Participants with gender discordance (FSTo0.2 for chromo-
some X SNPs to conﬁrm females and FST40.8 to conﬁrm males) were also
removed, unless their true identity could be determined. To verify and
correct potential misclassiﬁcation of self-reported race, we compared the
GWAS data from all participants with HapMap phase III reference
genotypes. Association tests were performed on N= 2116 using linear
regression models adjusted for age, sex and the ﬁrst three principal
component eigenvectors computed using Eigensoft and embedded in
generalized estimating equations to correct for correlations among
relatives.
Altogether, 2374 participants from FTC were included for replication
testing. These participants originated from the following cohorts: the
Nicotine Addiction Genetics study of adult twins born in 1938–1957 and
concordant for ever smoking, and their family members (mainly siblings); a
population-based longitudinal study of ﬁve consecutive birth cohorts
(1983–1987) of Finnish twins (FinnTwin12 sample); and a population‐based
longitudinal study of ﬁve consecutive birth cohorts (1975–1979) of Finnish
twins (FinnTwin16 sample).36–38 Genotyping was done with the Illumina
Human670-QuadCustom BeadChip (at the Wellcome Trust Sanger
Institute) and the Illumina HumanCoreExome BeadChip (at the Wellcome
Trust Sanger Institute and at the Broad Institute of MIT and Harvard). FTC
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samples were imputed with a large number of population samples,
separately by genotyping array, with reference to 1000 Genomes (Phase I
integrated variant set release [SHAPEIT2] in National Center for Biotech-
nology Information (NCBI) build 37 [hg19] coordinates) at the Institute for
Molecular Medicine Finland. After imputation, FTC samples were merged
together. Standardized residuals of the categorical FTND phenotype,
regressed against SNP dosages, age, sex, birth cohort and the 10 ﬁrst
principal components (calculated from genome-wide genotype data), were
used in QFAM association test in PLINK.17 The resulting regression
coefﬁcients are mathematically equivalent to regression coefﬁcients when
using raw phenotypes that are linearly regressed on SNP genotypes and
covariates, enabling us to combine the FTC results with the others in meta-
analysis as done elsewhere.39
UW-TTURC participants were recruited for nicotine dependence and
smoking cessation treatment clinical trials in Madison and Milwaukee,
Wisconsin beginning in 2001.12 We obtained their Illumina HumanOmni2.5
genotypes, FTND scores and other phenotypic data via dbGaP accession
number phs000404.v1.p1. After applying our standard QC procedures
(Supplementary Information), there were 1534 UW-TTURC participants
included in our study.
The GAIN and nonGAIN samples originated from the same Molecular
Genetics of Schizophrenia study. These companion samples were
genotyped separately, using the same platform (Affymetrix 6.0). Data
from half of the Molecular Genetics of Schizophrenia study participants
genotyped under the auspices of GAIN were obtained via dbGaP accession
number phs000021.v3.p2, and data from the other half of the Molecular
Genetics of Schizophrenia study participants (nonGAIN) were obtained via
dbGaP accession number phs000167.v1.p1. We used only schizophrenia
controls from GAIN (N= 774) and nonGAIN (N=671), for which we applied
our standard set of QC procedures (Supplementary Information).
Across the replication samples, the 1000 Genomes–imputed additive
genotype dosages for selected SNPs and indels were tested for association
with FTND-deﬁned nicotine dependence (mild, moderate and severe)
using linear regression models unless otherwise stated. Adjustments were
made for age, sex and eigenvectors (ﬁrst three for Yale-Penn and the
number needed to account for475% of the phenotypic variability for UW-
TTURC, GAIN and nonGAIN). Sample-speciﬁc results were combined, ﬁrst
across the replication samples and then across all GWAS and replication
samples, using inverse variance-weighted meta-analysis. Odds ratio
estimates, computed as eβ for moderate vs mild dependence and e2β for
severe vs mild dependence, were compared across all the samples using
the Forest Plot Viewer.40
Bioinformatics analyses
Linkage disequilibrium structure was discerned using LocusZoom41 or
Haploview42 with reference to the 1000 Genomes populations of
European-ancestry (denoted EUR). SNP annotations were taken from the
Ensembl genome browser.43
Splicing QTL analyses
To evaluate the regulatory potential of novel intronic SNPs in CHRNA4
associated with nicotine dependence, we ﬁrst used RNA-seq and genotype
data from the pilot phase of the Genotype-Tissue Expression (GTEx) project
to investigate SNP effects on splicing. GTEx captures a wide range of
tissues collected post-mortem from donors of any age from 21 to 70 years
old, sex and racial/ethnic group, although the data set is comprised mostly
of European-ancestry participants.44,45 Exclusions were made for HIV
infection or high-risk behaviors, viral hepatitis, metastatic cancer, recent
chemotherapy or radiation therapy, recent whole-blood transfusion or
body mass index at the extremes. We focused on the liver tissue, which
had the highest CHRNA4 expression levels among the GTEx tissues, and all
brain tissues combined, which had lower CHRNA4 expression levels but
high relevance for nicotine dependence.
An alternate CHRNA4 transcript (uc010 gke.1) encodes an additional
exon (designated 4.1 in Supplementary Figure 1) located between exons 4
and 5 of the major transcript (uc002.yes.2). We used split read counts
(reads crossing an exon:exon boundary) and a chi-square test to evaluate
the relative efﬁciency of splicing events, which utilize the exon 4 splice
donor and to query whether the efﬁciency varied by SNP genotype.
Expression QTL analyses
To further evaluate the regulatory potential of novel nicotine dependence-
associated SNPs, we conducted in silico testing of SNP associations with
transcript-level CHRNA4 mRNA expression using the Brain expression
quantitative trait loci (eQTL) Almanac.46 This resource contains genome-
wide cis-eQTL results, which were generated using Illumina Omni1-Quad
and Immunochip SNP genotypes, followed by 1000 Genomes imputation
and mRNA expression levels from Affymetrix Human Exon 1.0 ST arrays on
134 European-ancestry participants in the UK Brain Expression Consortium
data set.46 The participants, mostly adults, were free of neurodegenerative
disorders and were collected irrespective of nicotine dependence or any
other substance phenotype. Transcript-level and exon-level expression
measurements were made across 10 regions of the post-mortem brain
samples: cerebellar cortex, frontal cortex, hippocampus, inferior olivary
nucleus (sub-dissected from the medulla), occipital cortex, putamen (at the
level of the anterior commissure), substantia nigra, temporal cortex,
thalamus (at the level of the lateral geniculate nucleus) and intralobular
white matter. In addition to the single CHRNA4 transcript probe, probes
were available in each of the exons for the transcripts that provide
templates for a full-length CHRNA4 protein; no probe was available for the
ancillary exon 4.1 of the alternative transcript that results in a truncated
protein.
Follow-up SNP/indel association testing with lung cancer
For top nicotine dependence-associated SNPs, we performed in silico
testing of their associations with lung cancer using 1000 Genomes–
imputed GWAS meta-analysis results generated elsewhere.47 CHRNA4 SNP
results were provided using 12 160 cases and 16 838 controls from six
samples of European-ancestry: the International Agency for Research on
Cancer,48 Institute of Cancer Research,49 MD Anderson Cancer Center,50
National Cancer Institute (comprising EAGLE and the Prostate, Lung, Colon
and Ovary Study Cancer Screening Trial),51 Samuel Lunenfeld Research
Institute in Toronto51 and Helmholtz-Gemeinschaft Deutscher Forschungs-
zentren in Germany.51 SNP associations, adjusted for age, sex and the ﬁrst
two principal component eigenvectors, were evaluated using all lung
cancer cases and controls and using subsets of 3718 adenocarcinoma and
3422 squamous cell carcinoma cases. SNP associations with lung cancer
were also tested with adjustment for smoking history (ever vs never) and
pack-years of smoking among ever smokers (0 for never smokers) in three
of the case–control samples, which together comprised 16% never
smokers and 84% ever smokers.
RESULTS
Our GWAS meta-analysis included 17 074 ever smokers from ﬁve
European-ancestry samples (Table 1). We used the FTND to
categorize participants’ dependence as mild (N= 9137 with FTND
score 0–3 or low-level smoking), moderate (N= 4881 with FTND
score 4–6) or severe (N= 3056 with FTND score 7–10). We tested
genotyped and 1000 Genomes–imputed SNPs and indels for
association with categorical nicotine dependence in each sample
and then combined the GWAS results using inverse variance-
weighted meta-analysis with genomic control correction52 applied
to each sample. Meta-analysis results for the 9.9 million tested
SNPs/indels had no indication of bias (λgc = 0.97, Supplementary
Figure 2).
A novel genome-wide signiﬁcant association was observed on
chromosome 20q13 (lowest P= 3.8 × 10− 8 for rs4809294,
Figure 1a). In total, 23 SNPs/indels on chromosome 20q13 were
associated at Po5 × 10− 5 (Supplementary Table 1). We also
observed associations within the known gene clusters on chromo-
somes 15q25 (CHRNA5-CHRNA3-CHRNB4, lowest P= 3.5 × 10− 17)
and 8p11 (CHRNB3-CHRNA6, lowest P= 1.2 × 10− 6) (Figure 1a and
Supplementary Tables 2 and 3). None of the 23 top-associated
CHRNA4 SNPs interacted with previously established SNPs in the
known regions (Supplementary Table 4).
We tested the 23 CHRNA4 SNPs/indels associated with nicotine
dependence at Po5 × 10− 5 for independent replication using
7469 ever smokers from ﬁve European-ancestry samples (Table 1
and Supplementary Table 5). Two SNPs had genome-wide
signiﬁcant associations with nicotine dependence across all the
samples (Table 2): rs2273500 and rs6011779, which are in strong
linkage disequilibrium in European-ancestry individuals (D′= 1.00
and r2 = 0.70, Figure 1b and Supplementary Figure 3). Their minor
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alleles (frequency = 0.15 and 0.20) were associated with greater
nicotine dependence risk, as demonstrated in Figure 2 for the top
SNP rs2273500: meta-analysis odds ratio = 1.06 (95% conﬁdence
interval 1.04–1.08) for moderate vs mild nicotine dependence and
odds ratio = 1.12 (95% conﬁdence interval 1.08–1.17) for severe vs
mild nicotine dependence. None of the tested SNPs/indels
showed signiﬁcant evidence for between-sample heterogeneity
(Supplementary Table 6).
The top SNP from the overall meta-analysis, rs2273500, was
imputed well across our discovery and replication samples, with
info values ranging from 0.8 to 1.0 (Supplementary Tables 1 and
5). See the Supplementary Information for an evaluation of the
agreement between rs2273500 imputed dosages and directly
observed genotypes. rs2273500 is in some linkage disequilibrium
with rs4809294, the top GWAS-identiﬁed SNP (D′= 0.97 and
r2 = 0.37, Supplementary Figure 3). rs4809294 (replication meta-
Figure 1. SNP and indel associations with nicotine dependence from meta-analyses of discovery and independent replication samples, all of
European-ancestry. The − log10 (meta-analysis P) results are plotted by chromosomal position: (a) genome-wide meta-analysis results across
the ﬁve discovery samples (total N= 17 074) for 9.9 million genotyped and imputed SNPs and indels tested for association with nicotine
dependence (SNPs shown as circles and indels shown as triangles) with minor allele frequency 40.01 and (b) regional meta-analysis results
across all 10 discovery and replication samples (total N= 24 543) in the CHRNA4 gene on chromosome 20q13. For the regional plot, the r2
values between the top SNP (rs2273500, shown in purple) and other SNPs in the ﬂanking region were based on the 1000 Genomes European
reference panel (denoted EUR); the indels are shown in gray. The solid black lines mark the genome-wide statistical signiﬁcance threshold
(meta-analysis Po5× 10−8). indel, insertion/deletion; SNP, single nucleotide polymorphism.
CHRNA4 in a genome-wide nicotine dependence study
DB Hancock et al
5
Translational Psychiatry (2015), 1 – 11
Table 2. CHRNA4 SNPs and indels associated with nicotine dependence at genome-wide association study (GWAS) meta-analysis Po5 ×10− 5 and
followed up for independent replication testing
SNP/indel Minor allele Base pair position
(NCBI build 37)
SNP type MAFa GWAS sample meta-
analysis
(N=17 074)
Replication sample
meta-analysis
(N= 7469)
All sample meta-
analysis
(N=24 543)
β P β P β P
rs2273500 C 61 986 949 Intron 0.15 0.057 2.3 × 10− 6 0.061 9.2 × 10− 4 0.058 8.0× 10−9
rs6011779 C 61 984 317 Intron 0.20 0.049 6.0 × 10−6 0.059 5.5 × 10− 4 0.052 1.4× 10−8
rs6062901 G 61 980 261 Intron 0.18 0.050 7.0 × 10−6 0.055 2.1 × 10− 3 0.051 5.2 × 10− 8
rs6062899 G 61 979 793 Intron 0.19 0.049 9.8 × 10−6 0.054 2.4 × 10− 3 0.050 8.6 × 10− 8
rs4809543 A 61 986 950 Intron 0.074 0.086 3.0 × 10− 7 0.046 0.070 0.074 1.3 × 10− 7
rs45449494 G 61 987 930 Intron 0.080 0.079 5.7 × 10− 7 0.047 0.059 0.070 1.7 × 10− 7
rs45577732 G 61 983 934 Intron 0.078 0.082 4.6 × 10− 7 0.045 0.070 0.071 1.9 × 10− 7
rs201806007 AT 61 988 398 Intron 0.15 0.054 1.2 × 10− 6 0.054 5.3 × 10− 3 0.054 2.1 × 10− 7
rs151176846 C 61 997 500 Intron 0.076 0.083 4.4 × 10− 7 0.040 0.12 0.071 3.4 × 10− 7
rs45623037 C 61 989 658 Intron 0.080 0.078 7.2 × 10− 7 0.043 0.092 0.068 3.5 × 10− 7
rs4809294 A 61 977 723 3′-UTR 0.055 0.11 3.8× 10−8 0.027 0.38 0.085 3.8 × 10− 7
rs4809542 G 61 986 787 Intron 0.067 0.088 3.9 × 10− 7 0.035 0.19 0.072 7.1 × 10− 7
rs45618935 A 61 979 347 Intron 0.060 0.099 1.5 × 10− 7 0.028 0.35 0.079 7.3 × 10− 7
rs45461993 A 61 983 901 Intron 0.080 0.076 2.1 × 10− 6 0.044 0.088 0.067 8.4 × 10− 7
rs4809292 G 61 977 506 3′-UTR 0.061 0.096 2.2 × 10− 7 0.029 0.35 0.078 8.9 × 10− 7
rs199666656 T 61 975 634 3′-UTR 0.057 0.094 3.3 × 10− 7 0.026 0.39 0.075 1.6 × 10− 6
rs45497800 T 61 991 833 Intron 0.082 0.075 2.2 × 10− 6 0.035 0.16 0.064 2.0 × 10− 6
rs45456294 G 61 974 832 3′-UTR 0.062 0.092 6.2 × 10− 7 0.024 0.43 0.073 3.2 × 10− 6
rs45508092 G 61 974 731 3′-UTR 0.059 0.096 5.8 × 10− 7 0.025 0.40 0.076 3.2 × 10− 6
rs4809293 A 61 977 640 3′-UTR 0.048 0.12 7.2 × 10− 8 0.010 0.75 0.084 3.4 × 10− 6
rs45612034 A 61 974 970 3′-UTR 0.062 0.090 1.2 × 10− 6 0.024 0.42 0.072 5.0 × 10− 6
rs45470098 A 61 979 328 Intron 0.036 0.14 2.4 × 10− 7 0.0079 0.82 0.090 2.1 × 10− 5
rs144298540 T 61 984 931 Intron 0.049 0.10 4.1 × 10− 6 0.0045 0.88 0.068 1.3 × 10−4
Abbreviations: indel, insertion/deletion; MAF, minor allele frequency; SNP, single nucleotide polymorphism; UTR, untranslated region. aMAF was weighted by
sample size across all 10 samples. SNPs and indels are sorted by meta-analysis P-values across all the samples. P-values surpassing genome-wide signiﬁcance
threshold (Po5 × 10− 8) are in bold.
Figure 2. Association of the rs2273500 minor allele (C) with severe vs mild nicotine dependence across all the samples. rs2273500 had the
lowest P-value for its association with nicotine dependence in meta-analysis across all the samples, which are sorted by their size. Black-ﬁlled
diamonds indicate the discovery samples, and open diamonds indicate the replication samples. The odds ratio (OR) estimates are shown
proportional to the sample size. CI, conﬁdence interval; COGEND, Collaborative Genetic Study of Nicotine Dependence; COPDGene, Chronic
Obstructive Pulmonary Disease Gene Study; EAGLE, Environment and Genetics in Lung Cancer Etiology Study; FTC, Finnish Twin Cohort Study;
GAIN, Genetic Association Information Network GWAS of schizophrenia; nonGAIN, Molecular Genetics of Schizophrenia—nonGAIN sample;
SAGE*, Study of Addiction: Genetics and Environment (* indicates that overlapping COGEND participants were excluded); UW-TTURC,
University of Wisconsin-Transdisciplinary Tobacco Use Research Center.
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analysis P= 0.36) may tag an underlying causal variant with
varying linkage disequilibrium across the different populations,
and its effect size may have been overestimated in the discovery
GWAS meta-analysis.53
Prior genome-wide studies of CPD did not identify the CHRNA4
region at genome-wide signiﬁcance, likely owing to differences in
phenotype deﬁnition and lower SNP coverages.3–9,38,54,55 Regard-
ing phenotype deﬁnition, we found that our top SNP rs2273500
was most signiﬁcantly associated with time to ﬁrst cigarette in the
morning (P= 2.3 × 10− 8, Supplementary Table 7). In contrast, for
the missense CHRNA5 SNP rs16969968 that has reproducible
associations with both nicotine dependence (Supplementary
Table 1) and CPD,5–7 the lowest P-value, by far, was observed
for CPD (P= 9.4 × 10− 24, Supplementary Table 8). rs16969968 has
previously also shown strong association with cotinine levels,
which reﬂect recent nicotine intake.56,57
Regarding SNP coverage, our top nicotine dependence-
associated CHRNA4 variants are 1000 Genomes–imputed SNPs
not present on genotyping arrays or imputable from HapMap
phase II in prior GWAS. Our most signiﬁcantly associated SNP
available in HapMap phase II (rs4809539, r2 = 0.19 and D′= 0.67
with rs2273500 in EUR) had meta-analysis P= 3.5 × 10− 4. We
evaluated the CHRNA4 region further using meta-analysis results
from the largest prior GWAS of CPD by the Tobacco and Genetics
Consortium.7 These results are presented in Supplementary Table
9. Among 57 HapMap phase II SNPs in the region (r2 ranging from
0 to 0.61 with rs2273500 in EUR), we found that rs4809539 was
also the SNP that was most signiﬁcantly associated with CPD
(meta-analysis P= 4.8 × 10− 3); its T allele (frequency = 0.06) was
associated with higher CPD, consistent with an increased risk of
nicotine dependence in our data. These results suggest that use of
the FTND phenotype together with 1000 Genomes imputation
enabled us to detect CHRNA4 variant associations with nicotine
dependence that were genome-wide signiﬁcant.
Our top SNP rs2273500 is a splice acceptor variant that changes
the sequence at the 3′ end of the intron between exon 4 and an
ancillary exon, designated as exon 4.1 in Supplementary Figure 1;
the resulting alternate transcript is truncated and predicted to be
targeted for nonsense-mediated decay.43 To investigate the
rs2273500 effect on splicing, we obtained RNA-seq and genotype
data from the GTEx project.44 Liver (N= 32) showed the highest
CHRNA4 expression among the GTEx tissues, and transcripts
containing exon 4.1 were detected. Using split read counts (reads
crossing an exon:exon boundary) to test the efﬁciency of splicing
events that utilize the exon 4 splice donor, we found that
rs2273500-C resulted in signiﬁcant reduction of splicing to exon
4.1 in favor of increased splicing to exon 4.2 and to a cryptic splice
acceptor in exon 4.1 (P= 5.4 × 10− 58, Supplementary Table 10).
These results provide strong evidence that rs2773500 functions as
a splicing QTL.
Transcripts containing exon 4.1 were also observed in GTEx
brain tissue samples, but relative to the liver samples, their
frequencies were low (Supplementary Table 10). We observed the
same pattern, whereby rs2273500-C carriers had reduced splicing
to exon 4.1 and increased splicing to exon 4.2, but these
differences were not statistically signiﬁcant (P= 0.30) likely owing
to the limited statistical power with the lower split read counts.
However, we were able to evaluate rs2273500 as an eQTL SNP
reliably using CHRNA4 mRNA expression levels measured across
10 regions of physiologically normal human brains from 134
European-ancestry participants in the Brain eQTL Almanac.46,58 At
the transcript level (Supplementary Figure 4), we observed that
rs2273500-C was associated with decreased CHRNA4 expression in
intralobular white matter. In further evaluation of this brain region
(Figure 3), we found that rs2273500-C was associated with
decreased expression at CHRNA4 exons 2–6 (lowest P= 0.00073).
rs2273500 was next evaluated for its association with lung
cancer in 28 998 participants from six European-ancestry case–
control samples (Supplementary Table 11).47 rs2273500-C was
associated with increased lung cancer risk: meta-analysis odds
ratio = 1.06 (95% conﬁdence interval 1.00–1.12), particularly for
squamous cell carcinoma of the lung. However, the association
between rs2273500-C and lung cancer was likely mediated by
cigarette smoking, as it was no longer associated with lung cancer
when adjusted for smoking (Supplementary Table 12).
Figure 3. Associations of the top nicotine dependence-associated SNP rs2273500 with transcript-level and exon-level CHRNA4 mRNA
expression in intralobular white matter from 134 European-ancestry participants in the UK Brain Expression Consortium. The probe size (in
base pairs) is indicated, and P-values o0.05 are shown in bold. SNP, single nucleotide polymorphism.
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DISCUSSION
CHRNA4 has strong biological plausibility for inﬂuencing nicotine
dependence and consequently its adverse health effects. Nicotinic
acetylcholine receptor genes, including CHRNA4, encode subunits
that assemble together to form ligand-gated ion channels that
respond to the neurotransmitter acetylcholine. Nicotine exposure
from cigarette smoking also activates the receptors, triggering
dopamine release and inﬂuencing the reinforcing effect of
nicotine.59–61 The subunits encoded by CHRNA4 and CHRNB2
comprise α4β2 receptors, the most abundantly expressed nicotine
acetylcholine receptors in the brain. They have a high afﬁnity for
nicotine and serve critical roles in nicotine self-administration and
its positive reinforcement.62,63 Knock-out mouse models64,65 and
knock-in mice with a hypersensitive receptor66,67 have demon-
strated that CHRNA4 is a necessary and sufﬁcient factor for many
characteristic behaviors of nicotine dependence, including
nicotine-induced reward, tolerance and anxiety relief. A knock-
down rat model suggested that α4-containing receptors have a
role in nicotine-mediated analgesia, showing that reduced
CHRNA4 expression in brain signiﬁcantly attenuated sensitivity to
nicotine agonist.68 This is consistent with our ﬁnding that
rs2273500-C decreases CHRNA4 expression and, by lowering
sensitivity to nicotine’s effects, confers risk for nicotine depen-
dence. Further supporting the relevance of CHRNA4, highly
effective treatments for smoking cessation, varenicline69,70 and
cytisine,71 are partial agonists of α4β2 receptors. Interestingly, the
item with the strongest rs2273500 association (latency to smoke
in the morning) is the most robust of the FTND items in predicting
smoking cessation12 and has been associated with both lung
cancer72 and COPD.73
Prior studies in humans have supported CHRNA4 as a
susceptibility gene for nicotine dependence and other smoking
behaviors. Genome-wide signiﬁcant linkage signals have been
observed in the chromosome 20q13 region containing CHRNA4
for maximum number of cigarettes smoked in a 24-h period74 and
in the nearby chromosome 20q11 region for DSM-IV-deﬁned
nicotine dependence.75 Several candidate gene association
studies have focused on CHRNA4.76–89 Among the common SNPs
with reported associations, only rs2236196 was associated in our
study (P= 0.027, Table 3): its minor allele (frequency = 0.28)
conferring increased risk for nicotine dependence, consistent
with prior reports.76,82,83,85–87 rs2236196 shows some linkage
disequilibrium with rs2273500 (D′= 0.86 and r2 = 0.50,
Supplementary Figure 3). However, in a model including both
SNPs, the association remained for rs2273500 (P= 2.4 × 10− 5) but
not rs2236196 (P= 0.79) in meta-analysis across our GWAS
samples, indicating that our signal is distinct from the previously
reported SNP association. rs2273500 was presented in one of our
prior reports as having a suggestive, but nonsigniﬁcant, associa-
tion with nicotine dependence (N= 1929, P= 0.081).82 By using the
multidimensional FTND measure of physiological dependence
paired with 1000 Genomes imputation in a large sample, the
current study provides the ﬁrst genome-wide level of signiﬁcant
evidence supporting speciﬁc CHRNA4 variant associations with
nicotine dependence, which were not observed in prior studies of
CPD with larger sample sizes. Such phenotype differences have
similarly been observed for the established CHRNB3 region,
whereby genome-wide signiﬁcant variants were identiﬁed when
using FTND-deﬁned nicotine dependence but not when using
CPD.9
Rare variants in CHRNA4 have also been implicated as
contributing to nicotine dependence risk. A rare missense variant
allele in exon 5, R336C (rs56175056), which lowers the sensitivity
of the α4 receptor to nicotine exposure,90 has been associated
with increased risks of nicotine dependence and smoking-related
diseases, including lung cancer, chronic obstructive pulmonary
disease, peripheral artery disease and abdominal aortic T
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aneurysms.91 Another rare variant in exon 5, P451L (rs55915440),
was nominated for its association with decreased risk of nicotine
dependence92 but not independently corroborated.91 rs2273500
is located 5.2 kb from R336C and 5.5 kb from P451L; neither rare
variant was captured in our study owing to their frequencies.
Our study of common variants identiﬁed a splice site acceptor
variant allele (rs2273500-C) as being associated with (1) increased
risk of nicotine dependence at genome-wide signiﬁcance, (2)
decreased CHRNA4 expression in human brain and (3) increased
lung cancer risk likely through its effect on smoking. Future
studies with a large sample of brain-speciﬁc CHRNA4 exon-speciﬁc
sequences and FTND measurements are needed to validate and
elucidate the splicing mechanism involving rs2273500 and its
effect on nicotine dependence risk. Nonetheless, our new
evidence revealing a common SNP with important regulatory
features, along with a newly discovered functional rare variant,91
ﬁrmly establish CHRNA4 as an important susceptibility gene for
nicotine dependence and its adverse health consequences.
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